OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Subscription and Copyright Information	705
Subscription and Copyright Information	616
Advisory Board and Contents	302
Subscription and Copyright Information	291
Subscription and Copyright Information	258
Subscription and Copyright Information	233
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	230
Structural asymmetry in FGF23 signaling	218
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	203
Shearing of surface mucin saps tumor cell strength	196
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	177
Therapeutic inhibition of ferroptosis in neurodegenerative disease	160
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	152
Compstatins: the dawn of clinical C3-targeted complement inhibition	149
Swinging the SWI/SNF complexes for cancer therapy	147
Structural pharmacology and mechanisms of GLP-1R signaling	125
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Cancer pathogenesis and phase targeting through condensate fragility	123
Direct in vivo CAR T cell engineering	121
Advisory Board and Contents	120
Advisory Board and Contents	118
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	115
Advisory Board and Contents	114
A perspective on psychedelic teratogenicity: the utility of zebrafish models	112
Programmable CAR immunotherapies for neurodegenerative proteinopathies	111

Leveraging human microbiomes for disease prediction and treatment	104
Phenotypic approaches for CNS drugs	102
Engineering ACE2 decoy receptors to combat viral escapability	100
Nemolizumab (Nemluvio®) for prurigo nodularis	99
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	97
HSV-1 as a gene delivery platform for cancer gene therapy	96
Genetically engineered loaded extracellular vesicles for drug delivery	89
Ribosome-directed cancer therapies: the tip of the iceberg?	88
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	86
A deep dive into degrader-induced protein-protein interfaces	82
Optogenetic engineering for precision cancer immunotherapy	80
Subscription and Copyright Information	79
Mechanistic insights into nitazenes at the μ-opioid receptor	79
Engineering early immune resilience in islet transplantation	77
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	72
Thriving as members of under-represented groups in pharmacology-related careers	72
Subscription and Copyright Information	70
Emerging approaches to induce immune tolerance to therapeutic proteins	69
Subscription and Copyright Information	67
Now you serine, now you don't	67
Bimetallic nanoadjuvants for cancer vaccines	65
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	65
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	61
Suzetrigine for moderate to severe acute pain	61
Could dexmedetomidine be repurposed as a glymphatic enhancer?	61
Piezo1: structural pharmacology and mechanotransduction mechanisms	60
The structure, function, and pharmacology of MRGPRs	58
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	57
Autologous, allogeneic, in vivo CAR for autoimmune diseases	54